Epirus Biopharmaceuticals and mAbxience Sign Agreement on Infliximab Biosimilar Distribution in Latin America
Epirus Biopharmaceuticals and mAbxience have entered into a development and future distribution deal for Epirus’ lead program, BOW015 (infliximab, reference biologic Remicade), for Latin American markets.
Biosimilar company, Epirus Biopharmaceuticals, and mAbxience have entered into a development and future distribution deal for Epirus’ lead program, BOW015 (infliximab, reference biologic Remicade), for Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela.
Under the terms of the agreement, mAbxience, a biopharmaceutical company specializing in research, development, and manufacturing of biosimilars, will be responsible for regulatory submissions of BOW015 and the eventual commercialization of the compound in these select Latin American markets. Financial details of the agreement were not disclosed.
Source: Epirus BioPharmaceuticals
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
